Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. Show more
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (โAptoseโ or the โCompanyโ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0934 | -12.7945205479 | 0.73 | 0.74 | 0.59 | 111516 | 0.67603943 | CS |
4 | -0.1554 | -19.6212121212 | 0.792 | 0.8563 | 0.59 | 57717 | 0.70811554 | CS |
12 | -0.5734 | -47.3884297521 | 1.21 | 1.27 | 0.59 | 64180 | 0.948789 | CS |
26 | -1.5634 | -71.0636363636 | 2.2 | 2.3 | 0.59 | 79317 | 1.45776991 | CS |
52 | -3.7134 | -85.3655172414 | 4.35 | 5.1 | 0.59 | 63756 | 2.03868153 | CS |
156 | -41.3634 | -98.4842857143 | 42 | 46.875 | 0.59 | 346956 | 22.12313969 | CS |
260 | -43.7634 | -98.5662162162 | 44.4 | 138.7875 | 0.59 | 766264 | 64.82195412 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.